Ipsen claims that Dysport has become the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.

GSK will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS.

Following a turbulent funding environment, biotechs are seeking to generate more data earlier to reassure investors.

Trellis Bioscience has closed a $9m Series C round to support the completion of its ongoing Phase II trial evaluating calpurbatug for chronic PJI.

When the FDA approved Madrigal's Rezdiffra in 2024, it was the first marketed drug ever for MASH, which affects millions of American adults.

Precemtabart tocentecan is also being investigated in other oncology indications including gastric cancer, non-small cell lung cancer and pancreatic ductal ...

If approved, Keenova's Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.

Teva plans to start a Phase IIb study on TEV-‘408 in vitiligo during the final quarter of 2026 following positive results of a Phase Ib trial.

Kailera Therapeutics’ bet on Hengui Pharma’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA) appears to be paying off following two late-stage wins in obesity and type ...

Arrowhead's EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve.

More positive Phase II data from a subgroup further supports the trial expansion, which will lead further development.

Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a Phase III trial of Wainua (eplontersen) in transthyretin-mediated amy ...